The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation
Abstract
Src-specific activity has been reported to be elevated in a high percentage of colon cancer cell lines and tumors, but the underlying mechanisms are largely unknown. In this study, we report that, in the seven cancer cell lines tested, Src-specific activity was elevated (5.2- to 18.7-fold) relative to normal colon cells (FHC). This activation of Src correlated with reduced phosphorylation at Y530 of Src, whereas there was no significant change in the level of phosphorylation at Y419. The membrane tyrosine phosphatase activity for a Src family-specific phosphopeptide substrate FCP (Fyn COOH-terminal peptide phosphorylated by Csk) was greatly increased in the cancer cells and was attributed to PTP1B in most of the cell lines. Membrane PTP1B protein levels were also greatly increased. Overexpression of PTP1B increased Src specific activity in colon cancer cells by reducing phosphorylation at Y530 of Src. It also increased anchorage-independent cell growth and this increase was blocked by the Src inhibitor PP2 and Src small interfering RNA (siRNA). Down-regulating PTP1B activity by PTP1B inhibitor CinnGEL 2Me or knocking down PTP1B using siRNA also reduced Src kinase activity and colony formation ability of colon cancer cells. PTP1B siRNA reduced tumor growth in nonobese diabetic/severe combined immunodeficient mice. This study suggests that (a) PTP1B can act as an important activator of Src in colon cancer cells via dephosphorylation at Y530 of Src and (b) elevated levels of PTP1B can increase tumorigenicity of colon cancer cells by activating Src. [Cancer Res 2007;67(21):10129–37]
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PTP1b increased expression favors higher levels of src kinase activity by reducing Tyr530 phosphorylation.30”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [30]
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Crystal Structures of c-Src Reveal Features of Its Autoinhibitory Mechanism
Xu, W., Doshi, A., Lei, M., Eck, M. J., & Harrison, S. C. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80356-1 · Cited by 870
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592 · cited 1×
“tumors in mice and up to 4 weeks in nondividing mouse hepatocytes (41).”
BackgroundMutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer
Smith, G., Carey, F. A., Beattie, J., Wilkie, M. J. V., Lightfoot, T. J., Coxhead, J., Garner, R. C., Steele, R. J. C., & Wolf, C. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122612899 · Cited by 521 · cited 1×
“1), but the recent discovery of heterogeneous patterns of tumor mutations suggests that multiple alternative genetic pathways and/or other mechanisms might also lead to the development of colorectal cancer (2).”
BackgroundActivating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489 · cited 3×
“In one subset of advanced human colon cancers, increased Srcspecific activity has been linked to a mutation in the COOHterminal regulatory domain of Src (8).”
BackgroundInfluentialSelf-citationSalmeen, A., Andersen, J. N., Myers, M. P., Tonks, N. K., & Barford, D. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00137-4 · Cited by 467
Selected glimpses into the activation and function of Src kinase
Bjorge, J. D., Jakymiw, A., & Fujita, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203923 · Cited by 412
Self-citationIncrease in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
PTP1B: From the sidelines to the front lines!
Tonks, N. K. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00603-3 · Cited by 371
Bjorge, J. D., Pang, A., & Fujita, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004852200 · Cited by 316 · cited 10×
“Subconfluent cells in tissue culture dishes were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer freshly supplemented with phosphatase and protease inhibitors ( 22 ).”
BackgroundMethodResultInfluentialSelf-citation
Cited by
EGF receptor trafficking: consequences for signaling and cancer
Tomas, A., Futter, C. E., & Eden, E. R. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.11.002 · Cited by 779
Krishnan, N., Fu, C., Pappin, D. J., & Tonks, N. K. (2011) · Science Signaling · doi:10.1126/scisignal.2002329 · Cited by 446
“PTP1B activates the protein tyrosine kinase SRC, a 60-kD protein, by dephosphorylating the C-terminal inhibitory phosphorylation site, Tyr(527), thereby promoting autophosphorylation of SRC on Tyr(416), a process that is required for robust kinase activity (35, 36).”
BackgroundSrc signaling in cancer invasion
Guarino, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22011 · Cited by 426
“The phosphatase PTP1B, which is upregulated in human colon cancer cells, is responsible for the dephosphorylation of Tyr530 and the subsequent activation of Src and, therefore, enhanced tumorigenicity (Zhu et al., 2007).”
BackgroundThiol-based redox switches in eukaryotic proteins
Brandes, N., Schmitt, S., & Jakob, U. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2285 · Cited by 373
“Furthermore, PTP1B appears to have oncogenic properties in various cancer types such as in colon cancer, where it activates Src by catalyzing the dephosphorylation of the negative regulator residue Tyr530 (154).”
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor
Krishnan, N., Koveal, D., Miller, D. H., Xue, B., Akshinthala, S. D., Kragelj, J., Jensen, M. R., Gauss, C.-M., Page, R., Blackledge, M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1528 · Cited by 372
“Furthermore, PTP1B plays a positive role in promoting the tumor phenotype in gastric cancer, where its expression is correlated with metastasis 27,28 , as well as in prostate 29 and colon 30 cancer cells.”
Metadata
- Authors
- Zhu, S., Bjorge, J. D., & Fujita, D. J.
- Affiliations
- University of Calgary (CA)
- Venue
- Cancer Research
- Published
- 2007-11-01
- Volume
- 67
- Issue
- 21
- Pages
- 10129-10137
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2132926900
- Cited by
- 168
- References
- 51
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 1 · 2023: 10 · 2022: 9 · 2021: 9 · 2020: 8 · 2019: 6 · 2018: 6 · 2017: 10 · 2016: 13 · 2015: 12 · 2014: 9 · 2013: 11 · 2012: 8
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- PTP1B, Src kinase activation, colon cancer, protein tyrosine phosphatase, anchorage-independent growth, tumorigenicity, PP2, siRNA knockdown, tumor growth in nude mice
- MeSH terms
- Animals, Colonic Neoplasms, Enzyme Activation, Humans, Male, Phosphorylation, Mice, SCID, src-Family Kinases, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-fyn, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-4338
- The paper
- Zhu, S., Bjorge, J. D., & Fujita, D. J. (2007). PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-4338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.